[Explanation] Recently, the results of the seventh batch of centralized procurement of drugs organized by the state in China have been released. This time, 60 drugs have been successfully purchased. Among them, the average price of the anti-tumor drug lenvatinib has dropped by more than 85%.
[Concurrent] Lu Yun, Professor of International Pharmaceutical Business School of China Pharmaceutical University
In the seventh batch of centralized procurement, the varieties with a relatively large decline may be mainly concentrated in the varieties with a relatively fierce competition pattern. For example, 28 companies will only retain 10 (of) omeprazole injection; some have a relatively large decline. Yes, it turns out that the price itself is relatively high, or some drugs that have just passed the patent period, such as our lenvatinib mesylate capsules and tirofiban injections, which cost more than 100 yuan per tablet, and so on. The drop is more than 85%.
[Explanation] As a first-line targeted drug for liver cancer, lenvatinib is used for the treatment of patients with unresectable hepatocellular carcinoma who have not received systemic therapy before. Due to its outstanding efficacy, it has been widely used in clinical practice.
Lu Yun said that the lowest price of lenvatinib capsules in this batch of centralized procurement was 3.6 yuan per capsule, a decrease of 97%.
[Concurrent] Lu Yun, Professor of International Pharmaceutical Business School of China Pharmaceutical University
Although lenvatinib is used as a first-line liver cancer drug, when we watched it on the spot, one manufacturer actually quoted more than 3 yuan (3.6 yuan/capsule) at the lowest price, that is, the highest drop was 97%. In fact, we were still a little surprised. of.
[Explanation] According to the data of the National Medical Insurance Bureau, the seven batches of centralized drug procurement organized by the state that have been carried out cover 294 kinds of drugs, and the average price of drugs has dropped by more than 50%.
[Concurrent] Liu Ying, clinical pharmacist, Department of Pharmacy, China-Japan Friendship Hospital
Whether our drug is this batch or the previous batches, whether it is the same product or imported original research product, it has received a corresponding reduction in price.
What impressed me the most was our special collection of insulin. The last batch has now been put into practice in Beijing, because diabetic patients must use insulin for life. It turns out that we imported original research, such as ultra-long-acting insulin, such as It is said that "Dite" and "Ganjing" are more than 180 yuan each, and now they are only a few dozen yuan.
[Explanation] Lu Yun introduced that the price reduction of centralized procurement may reduce the profit of enterprises due to price reduction in the short term, but at the same time, centralized procurement, through the basic principles of integrating recruitment and procurement, and linking volume and price, greatly saves the company's sales costs, while optimizing Internal management to save costs.
[Concurrent] Lu Yun, Professor of International Pharmaceutical Business School of China Pharmaceutical University
For a long time, when we look back, we can see that the enthusiasm of our enterprises to participate in centralized procurement has not decreased but increased, and has gradually become the beneficiary of this reform.
Our centralized procurement has systematically reshaped the industry ecology, prompting our pharmaceutical industry to shift from high-speed growth to high-quality development, and guiding our corporate investment focus from marketing to R&D.
Reported by Dong Zeyu and Li Chun in Beijing
Responsible editor: [Li Ji]